Definium Therapeutics, Inc.
DFTX
$17.64
-$0.45-2.49%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -45.18% | -391.56% | -630.17% | 57.08% | -45.58% |
| Total Depreciation and Amortization | -- | -- | -- | -- | 100.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 22.18% | 755.64% | 147.32% | -109.51% | 54.93% |
| Change in Net Operating Assets | -1,805.33% | 703.17% | 334.46% | -263.52% | 94.07% |
| Cash from Operations | -69.52% | -71.99% | -48.08% | -77.24% | -23.28% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | 320.00% | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 6,644.31% | -99.00% | -96.66% | -99.44% | 47.32% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -21,161.33% | 100.00% | 78.89% | -- | -78.57% |
| Cash from Financing | 6,358.31% | -98.92% | 82.15% | -99.41% | 46.82% |
| Foreign Exchange rate Adjustments | 0.00% | -90.91% | 2,400.00% | 42.86% | 104.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,204.20% | -125.76% | -437.63% | -225.07% | -19.72% |